Cancer cell molecular mimicry of stem cells (SC) imbues neoplastic cells with enhanced proliferative and renewal capacities. In support, numerous mediators of SC selfrenewal have been evinced to show oncogenic potential. We have recently reported that short-hairpin RNAmediated knockdown of the embryonic stem cell (ESC) self-renewal gene NANOG significantly reduced the clonogenic and tumorigenic capabilities of various cancer cells. In this study, we sought to test the potential pro-tumorigenic functions of NANOG, particularly, in prostate cancer (PCa). Using qRT-PCR, we first confirmed that PCa cells expressed NANOG mRNA primarily from the NANOGP8 locus on chromosome 15q14. We then constructed a lentiviral promoter reporter in which the À3.8-kb NANOGP8 genomic fragment was used to drive the expression of green fluorescence protein (GFP). We observed that NANOGP8-GFP þ PCa cells showed cancer stem cell (CSC) characteristics such as enhanced clonal growth and tumor regenerative capacity. To further investigate the functions and mechanisms of NANOG in tumorigenesis, we established tetracyclineinducible NANOG-overexpressing cancer cell lines, including both PCa (Du145 and LNCaP) and breast (MCF-7) cancer cells. NANOG induction promoted drug resistance in MCF-7 cells, tumor regeneration in Du145 cells and, most importantly, castration-resistant tumor development in LNCaP cells. These pro-tumorigenic effects of NANOG were associated with key molecular changes, including an upregulation of molecules such as CXCR4, IGFBP5, CD133 and ALDH1. The present gain-offunction studies, coupled with our recent loss-of-function work, establish the integral role for NANOG in neoplastic processes and shed light on its mechanisms of action.
Introduction
Immortality is among the fundamental biological properties of malignant cells attributable to the presence of a distinct subset of stem-like cells within tumors. Self-renewing neoplastic cells have been hypothesized to underlie the long-term proliferative potential of cancer cells, often sharing gene expression profiles with embryonic stem cells (ESCs) or primitive somatic SCs (Ben-Porath et al., 2008; Wong et al., 2008; Liu et al., 2009; Pece et al., 2010) . Numerous studies over the past several years have provided solid evidence for the existence of such cancer-sustaining stem-like cells, generally termed 'cancer stem cells' (CSCs) or 'tumorinitiating cells' (Al-Hajj et al., 2003; Singh et al., 2003; Patrawala et al., 2006; O'Brien et al., 2007; Boiko et al., 2010) . However, the molecular framework within which cancer cells fit into the SC paradigm and how this relates to the development of clinical manifestations of late-stage disease, including resistance to conventional therapeutics, tumor relapse and metastasis, remains obscure.
Infinitely self-renewing cells (that is, CSCs) could conceivably account for the immortal nature of tumor cells at the population level, and accumulating evidence supports the notion that ESC self-renewal and pluripotency genes, including the transcription factor triad OCT-3/4 (that is, OCT-4), SOX-2 and, of particular interest, NANOG, serve as neoplastic engines driving oncogenesis (Hochedlinger et al., 2005; Piestun et al., 2006; Gangemi et al., 2009; Jeter et al., 2009; Liu et al., 2009; Po et al., 2010; Zbinden et al., 2010) . Previously, we evaluated the causal relationship between the expression of NANOG in human epithelial cancer cells and tumor development . We found that NANOG mRNA in somatic cancer cells appeared to originate predominantly from NANOGP8, a retrogene derivative distinct from the NANOG1 locus expressed in ESCs, and that NANOGP8 mRNA was enriched in CD44 þ prostate cancer (PCa) stem/progenitor cells and in MCF7 side population cells. Further, we showed that the NANOG protein was heterogeneously expressed as a 'gradient' in xenograft as well as primary prostate tumor cells. Of particular importance, we observed that NANOG knockdown decreased the clonogenic growth and tumorigenicity of breast (MCF-7), colon (Colo320) and several prostate (PC3, Du145 and LAPC-9) cancer cell lines and xenografts . These results raise an important question of whether NANOG expression actively promotes neoplasia and/or tumor progression. Here, we address this question by further investigating the origins of NANOG in cancer cells, particularly, in PCa, and exploring its oncogenic potential and associated mechanisms.
Results
NANOGP8 mRNA expression in PCa, including primary patient tumors (HPCa) Our first aim in the present study was to determine whether cancer cells expressing endogenous NANOG are intrinsically unique compared with their nonexpressing (or low-expressing) counterparts. To this end, we conceived a promoter reporter strategy to track and isolate cells differentially expressing NANOG. However, one complication is that at least two highly similar NANOG mRNA species have been reported originating from two distinct loci (Figure 1a ), including the NANOG1, located on chromosome 12p13, in ESCs, and its retrogene NANOGP8, located on chromosome 15q14 (Booth and Holland, 2004) . Given their remarkable similarity (highly conserved over the entire length of the processed transcripts, with only six nucleotide substitutions in the coding regions and 99% identical at the amino-acid level) , theoretically, NANOG1 and/or NANOGP8 could account for the presence of NANOG mRNA in cancer cells. We previously provided preliminary evidence that NANOGP8 was the predominant source of NANOG mRNA in epithelial cancer cells, including PCa ; however, due to methodological limitations we could not eliminate NANOG1 as an important contributor. Thus, we set out to further investigate the origin of NANOG mRNA using quantitative reverse transcription-PCR (qRT-PCR) analysis.
We designed NANOG1-and NANOGP8-specific qRT-PCR primers and probes ( Supplementary Table  S1 ) by targeting a unique 22-bp region in the NANOG1 3 0 -untranslated region Figure 1a ). NANOGP8 mRNA was readily detectable in a range of cancer cell lines, including those derived from breast (MCF7), colon (Colo320) and PCa (LNCaP, Du145 and PC3), as well as in LAPC4 and LAPC9 PCa xenografts ( Figure 1b ). As might be expected, LNCaP, the most benign PCa line, expressed the least NANOGP8 mRNA (Figure 1b ). By contrast, NANOG1 qRT-PCR in the same panel of cancer cells (using identical template used in NANOGP8 amplifications) was generally below the detection limit (that is, cycle threshold (C t ) 438), although these same primers robustly amplified the product from N-TERA teratocarcinoma cells (C t of 21) (data not shown). Importantly, a cohort of seven primary PCa patient samples (human PCa (HPCa)) and two early xenografts (that is, HPCa58P1 and HPCa101P0) also expressed readily detectable NANOGP8 mRNA (Figure 1c ), whereas NANOG1 was undetectable (that is, C t 438) in all samples (not shown). Consistent with earlier findings , primary PCa specimens expressed higher relative levels of NANOGP8 mRNA than cultured PCa cells (compare Figures 1c and 1b) . Interestingly, the two HPCa samples (that is, HPCa58 and HPCa101) that successfully gave rise to xenografts upon transplantation in NOD/SCID mice expressed higher levels of NANOGP8 mRNA than the other five HPCa samples ( Figure 1c ). Upon in vivo passaging, HPCa58P1 showed reduced whereas HPCa101P0 showed increased NANOGP8 mRNA Figure 1 The NANOG genomic loci and NANOG mRNA expression in PCa cells. (a) Schematic of NANOG1 and NANOGP8 gene structures. Chr, chromosome; E, exon; UTR, untranslated region. The 22-bp region unique to NANOG1 (vertical bar) was used to design primers/probes for NANOG1-and NANOGP8specific PCR. (b) Quantitative PCR (qPCR) detection of NANOGP8 mRNA expression in various cancer cells, normalized to GAPDH. The normalized NANOGP8 mRNA levels in LNCaP cells were set at 1 and NANOGP8 mRNA levels in breast (MCF7), colon (Colo320) and PCa cell lines (LNCaP, Du145 and PC3) and xenografts (LAPC-4 and LAPC-9) were presented relative to LNCaP. (c) NANOGP8 mRNA levels in a cohort of primary patient tumors (HPCa) as determined by qPCR. HPCa56P1 and HPCa101P0 are two early-passage (P) xenografts established in our laboratory. PCa, prostate cancer; GAPDH, glyceraldehyde-3phosphate dehydrogenase; HPCa, human PCa. levels (Figure 1c ), suggesting that passaging of HPCa tumors in mice may alter the expression levels of NANOGP8 mRNA.
A NANOGP8-GFP promoter reporter tracks subsets of PCa cells enriched in clonogenic and tumorigenic properties The above qRT-PCR analyses are consistent with our previous semi-quantitative RT-PCR data and confirm that NANOGP8 mRNA is the predominant NANOG mRNA species in PCa (and some other cancer) cells. Consequently, we replaced the constitutive and ubiquitous phosphoglycerate kinase (PGK) promoter in the RRL-PGK-GFP lentiviral vector (Zufferey et al., 1998) with the B3.8-kb region (nucleotides À3764 to þ 58) upstream from the NANOGP8 Transcription Start Site (TSS) to construct the RRL-NP8-GFP vector (Figure 2a ). Fluorescence-activated cell sorting (FACS) analysis of PGK-GFP-transduced PCa cells showed that in LNCaP and Du145 cells, 80-90% cells were GFP þ at 2 ml of virus and only slightly more cells became GFP þ at 20 ml of virus (Figure 2b and Supplementary Figure S1a ). PC3 cells infected with the PGK-GFP vector, on the other hand, showed a viral titer-dependent increase in GFP þ cells (Figure 2b ). In comparison, only a very small percentage of PCa cells were GFP þ upon transduction with 2 ml of NP8-GFP lentivirus, prepared in parallel (Figure 2b and Supplementary Figure S1a ). Even at 20 ml of virus, only B19% LNCaP cells and B34% Du145 cells were NP8-GFP þ (Figure 2b ). For PC3 cells, even at 100 ml of virus, o10% cells infected with the NP8-GFP were GFP þ (Figure 2b ). These results suggest that, as we previously reported ), NANOG-expressing PCa cells are generally rare and NANOGP8 mRNA levels in cultured PCa cells are low, consistent with the preceding qRT-PCR analysis (Figure 1b ). Of note, Du145 cells expressed NP8-GFP as a clear gradient with increasing volumes of virus, reaching B80% GFP þ cells at 100 ml of virus ( Figure 2b ). These observations parallel our previous reports of NANOG protein expression as a gradient and NANOG protein being more readily detectable in Du145 cells relative to PC3 or LNCaP cells . Immunofluorescence (IF) staining of LNCaP cells transduced with NP8-GFP showed concordant expression of NANOG and green fluorescence protein (GFP) in these cells (Figure 2c ). Using the denaturation immunostaining protocol , we observed B10-fold enrichment of NANOG-positive cells in purified NP8-GFP þ LNCaP cells compared with that in bulk LNCaP cells (not shown). Moreover, qRT-PCR analysis showed NANOG mRNA levels in NP8-GFP þ versus NP8-GFP À PC3 cells to be 2.02% versus 0.11% relative to the levels in N-TERA human embryonal carcinoma cells, indicating an 18-fold enrichment of NANOG mRNA in NP8-GFP þ PC3 cells. Taken together, these results suggest that PCa cells expressing the promoter constructs are enriched in NANOG mRNA and protein expression.
Next, we set out to test the biological characteristics of RRL-transduced and sorted Du145, PC3 and LNCaP cells. Du145 NP8-GFP þ cells, compared with NP8-GFP À cells, generated more holoclones, meroclones and paraclones (Figure 2d ), morphologically distinct classes generally thought to reflect the differentiation state of the originating cell, with the holoclones containing the long-term self-renewing CSCs (Li et al., 2008) . By contrast, purified PGK-GFP þ and PGK-GFP À Du145 cells showed similar cloning efficiency (CE) (Supplementary Figure S1b ). PC3 NP8-GFP þ cells also showed enhanced CE (Figure 2e ) and further, gave rise to larger clones compared with NP8-GFP À PC3 cells (3949± 1462 versus 2278±912, respectively; P ¼ 0.04). Interestingly, NP8-GFP þ and NP8-GFP À LNCaP cells showed similar CE in standard serum-containing media. However, in androgen-deprived conditions, that is, in media containing charcoal dextran-stripped serum (CDSS) and/or anti-androgen bicalutamide, purified NP8-GFP þ LNCaP cells showed significantly higher CE than the NP8-GFP À cells (Figure 2f and Supplementary Figure  S2a ). These latter observations in LNCaP cells provided the first evidence that NANOG might be associated with resistance to androgen deprivation.
Finally, we assayed the quintessential biological property of CSCs, that is, tumor development. NP8-GFP-transduced Du145 cells, initially 30% GFP þ , were sorted into 7-aminoactinomycin-D (7AAD)-negative (that is, viable) NP8-GFP À and NP8-GFP þ subsets, and injected subcutaneously (s.c.) into NOD/SCID mice. The primary (1 o ) Du145-NP8-GFP þ tumors were not only larger than those derived from Du145-NP8-GFP À cells (Figure 2g ), but also comprised a mixture of GFP þ (41%) and GFP À cells (not shown), thus recapitulating the heterogeneity of the starting population, and suggesting that the NP8-GFP þ cells could divide asymmetrically to give rise to NP8-GFP À cells. NP8-GFP þ Du145 cells purified from the 1 o tumors also regenerated tumors B60% larger than NP8-GFP À cellderived tumors (not shown). Histological analysis showed more readily detectable NANOG-expressing and Ki-67 þ cells in tumors derived from NP8-GFP þ Du145 cells (Supplementary Figure S2b ). Similar to NP8-GFP þ Du145 cells, the NP8-GFP þ PC3 cells also generated larger tumors than their NP8-GFP À counterparts in both 1 o and 2 o tumor assays ( Figure 2h ). Collectively, the promoter-tracking studies show that the NANOGP8-expressing PCa cells possess higher clonal and tumor-regenerating capacities, characteristics associated with and expected of CSCs.
Establishing an inducible NANOG-overexpressing lentiviral system
The second principal aim of this study was to determine the cellular and molecular mechanisms underpinning the biological functions of NANOG in cancer cells. As NANOG is normally expressed at low levels in cultured epithelial cancer cells relative to ESCs , we engineered a tetracycline (doxycycline, dox)inducible lentiviral system to overexpress NANOG ( Figure 3a ). Cancer cells (MCF7, Du145 and LNCaP) initially infected with the pLVX-TetON lentivirus ( Figure 3a ) and expressing high levels of the dox-inducible transactivator (TetR/VP16) were clonally derived by analysis of expression of a Tetracyclineresponsive element (TRE) luciferase reporter (data not shown). Stable clones were then subjected to 21 transductions with either pLVX empty vector or the pLVX-TRE-Nanog1/NanogP8 lentiviral vectors in which the NANOG1 or NANOGP8 cDNA was cloned downstream from the TRE (Figure 3a ). Western blot analysis showed dox-induced upregulation of NANOG protein in a dose-dependent manner (Figures 3b and c; note that most commercial anti-NANOG antibodies (Abs) were generated against NANOG1 and recognize both NANOG1 and NANOGP8 on western and IF; Jeter et al., 2009 ). The induced NANOG protein (for the sake of simplicity, both NANOG1 and NANOGP8 proteins will frequently be termed NANOG henceforward due to nearly identical amino-acid sequences) was mostly detected in the nucleus (Figures 3d and e and Supplementary Figure S3 ), a subcellular localization expected for a transcription factor. In the absence of dox, NANOG-expressing Du145 (Figure 3d ) and MCF7 (Supplementary Figure S3 ) cells were rare and NA-NOG-expressing LNCaP cells were even more rare (Figure 3e To evaluate whether the overexpressed NANOG protein is functional, we performed NANOG chromatin immunoprecipitation (ChIP) assays followed by PCR using primers against several reported gene targets of NANOG1 in human ESCs, including c-Myc, Oct-4, Ecadherin, FGF4, Gli1 and HoxC13 (Medeiros et al., 2009 and Supplementary Figure S4 ). We first performed ChIP assays in N-TERA cells and the results showed differential NANOG protein binding to the individual NP8-GFP þ LNCaP cells showed increased CE only under androgen-deprivation conditions. (g, h) NP8-GFP þ PCa cells are more tumorigenic than NP8-GFP À cells. FACS-purified GFP þ /À cells were injected s.c. in Matrigel in NOD/SCID-g recipients. (g) 5K each of NP8-GFP þ /À Du145 cells were injected and tumors were harvested at B2 months. (h) 1K each of purified NP8 þ /À PC3 cells were injected s.c. in the 11 and 21 tumor transplantation experiments (harvested at day 56 and day 49, respectively). Shown are the pooled data. 7AAD, 7-aminoactinomycin-D; CDSS, charcoal dextran-stripped serum; CE, cloning efficiency; CSC, cancer stem cell; FACS, fluorescence-activated cell sorting; PCa, prostate cancer; s.c., subcutaneously. gene promoters (Figure 4a ). ChIP assays in NANOG1and NANOGP8-overexpressing (that is, pLVX-Na-nog1/NanogP8) LNCaP cells showed that dox-induced NANOG also bound to the promoter regions of these genes (Figure 4b ), although the levels of binding, after normalizing to RbIgG ChIP, was expectedly lower than in N-TERA cells (compare Figures 4b and c with 4a ). Similar ChIP assays did not show significant binding of either NANOG1 or NANOGP8 at the GAPDH promoter ( Figure 4c ). Altogether, the IF and ChIP assays indicate that the overexpressed NANOG1/ NANOGP8 proteins in our inducible systems localize to the nucleus and are functional in binding the expected targets.
Short-term NANOG induction does not promote cancer cell proliferation
Having successfully established an inducible system to overexpress functional NANOG, we next sought to determine the biological responses to elevated NANOG protein in cancer cells. As NANOG overexpression had been previously reported to enhance proliferation in several cell types, including NIH3T3 cells (Zhang et al., 2005) , ESCs and colorectal cancer cells (Meng et al., 2010) , we first performed short-term assays in which our inducible NANOG cell lines were stimulated with dox for 3-4 days prior to counting the total cell number. To our surprise, under standard culture conditions no significant difference was apparent in pLVX-control versus pLVX-Nanog1/P8 LNCaP, Du145 or MCF-7 cells (Supplementary Figure S5a; data not shown). Bromo-deoxyuridine (BrdU) incorporation assays also did not show any differences (Supplementary Figure S5b ), suggesting that increased short-term NANOG expression did not promote cell proliferation in these cancer cells. Consistent with this observed lack of phenotype, western blot analysis of short-term (B3-4 days) dox-treated Du145, LNCaP and MCF-7 cells showed that despite a clear induction of NANOG protein, there was no detectable change in the levels of several positive regulators of the cell cycle, including CDC25A and CDK6, previously reportedly to be transcriptionally upregulated in response to NANOG overexpression in human ESCs , as well as cyclin-D1 and the c-Myc oncogene (Supplementary Figure S5c and d) . Similar to these cell-cycle regulators, several SC molecules, including Sox2, Oct4, Gli1, Nkx3.1 and CD44, as well as two molecules associated with epithelial-mesenchymal transition, that is, Snail and E-cadherin, also did not show significant changes upon short-term NANOG1/NANOGP8 induction ( Supplementary Figure S5c and d) .
NANOG overexpression promotes castration-resistant phenotypes and tumor regeneration in LNCaP cells
Although short-term induction of NANOG did not promote cancer cell proliferation, it promoted anchorage-independent survival and sphere formation in LNCaP cells in androgen-deficient conditions, generally assayed longer term (2-4 weeks). Two independent experiments showed that pLVX-NanogP8 but not pLVX-Nanog1 LNCaP cells generated B2 Â more spheres in methylcellulose than pLVX-control cells (Figure 5a ). On the other hand, both pLVX-Nanog1 and pLVX-NanogP8 LNCaP cells cultured in CDSS, compared with pLVX control cells, formed more androgen-independent (AI) foci and floating spheroids (Figures 5b and c) , and resulted in higher cell numbers (Figure 5d ).
Next, we determined the impact of NANOG overexpression on LNCaP tumor development in either intact (androgen-proficient) or castrated (surgical castration plus bicalutamide treatment; see section Materials and methods) NOD/SCID-g mice. We observed that NANOG overexpression promoted LNCaP tumor regeneration in intact hosts, but in a somewhat inconsistent manner. For example, pLVX-Nanog1 cells developed larger tumors than pLVX cells in one (Figure 5e ) but not the other (Figure 5f ) experiment. pLVX-NanogP8 cells, on the other hand, regenerated larger tumors than pLVX cells, but in both experiments the difference were just below statistical significance (Figures 5e and f) . By contrast, both pLVX-NanogP8 and pLVX-Nanog1 cells developed significantly larger tumors than the control cells in castrated NOD/SCID-g mice (Figures 5f and g) . Of note, qRT-PCR and immunohistochemical (IHC) analysis showed overall similar levels of NANOG mRNA and protein expression in the pLVX-NANOG1 and pLVX-NANOGP8 LNCaP tumors developed in intact (Supplementary Figure S6a , left; Supplementary Figure S6b ) or castrated (not shown) hosts. Interestingly, when we derived tumor cells from the LNCaP AI tumors and analyzed their migratory capacities by time-lapse video microscopy, we observed that NANOGP8expressing AI cells possessed a higher migration rate such that they closed the induced 'wounds' faster than the pLVX control or pLVX-Nanog1 cells (Figure 5h ).
Molecular changes that accompany NANOG overexpression in LNCaP cells
Given that NANOG-overexpressing LNCaP cells both in vitro and in vivo showed enhanced hormone refractory growth, we wondered what molecular mechanisms could account for this resistance to androgen deprivation. IHC analysis of AI tumors developed in castrated hosts (Figure 5g ) showed significantly more Ki-67 þ cells in both pLVX-Nanog8 and pLVX-Nanog1 tumors (Figure 6a ), suggesting that NANOG overexpression promotes cell proliferation in vivo. Consistent with this conclusion, the pLVX-Nanog1 AI tumors, and, in particular, the pLVX-NanogP8 AI tumors, showed higher levels of c-Myc compared with the control tumors (Figure 6b ). By contrast, we did not observe obvious differences in Ki-67 þ cells in the LNCaP tumors developed in intact male mice (Supplementary Figure S6c ). Previously, we provided preliminary evidence that NANOG and androgen receptor (AR) seemed to be reciprocally expressed in HPCa cells in patient tumors ). IHC (Figure 6a ) and western blotting analysis (Figure 6c ) detected reduced AR levels in pLVX-Nanog1/NanogP8 LNCaP AI tumors. In fact, even in short-term in vitro assays, both clone B2 (Figure 6d ) and clone D2 (Supplementary Figure S5c ) LNCaP cells, upon NANOG1/NANOGP8 induction, showed subtle but reproducible decreases in AR. Consistent with reduced AR levels, the pLVX-Nanog1/NanogP8 LNCaP AI tumors also showed reduced levels of prostate-specific antigen (PSA) (Figure 6a ). Pilot experiments with a PSA promoterdriven GFP reporter also showed that the pLVX-Nanog1/NanogP8 LNCaP cell cultures had B20% and 18%, respectively, less GFP þ cells than pLVX control LNCaP cells (data not shown). In principle, increased cell proliferation (that is, increased Ki-67 þ cells associated with c-Myc upregulation) and inhibition of differentiation (that is, reduced AR and PSA) could help explain how NANOG1/NANOGP8 promoted LNCaP AI tumor regeneration. To further explore the potential molecular mechanisms of NANOG-promoted castration-resistant properties in LNCaP cells, we analyzed, by qRT-PCR, the mRNA levels of a panel of molecules ( Supplementary  Table S1 and S3), which encompasses reported NANOG targets in ESCs (OCT-4 and SOX-2), CSC markers (CD133, CD44, c-KIT/CD117, ALDH1 (aldehyde dehydrogenase-1) and ABCG-2/BCRP) and molecules previously implicated in PCa castration resistance (IGFBP5, CXCR4 and Bcl-2). As shown in Figure 6e , insulin growth factor-binding-protein-5 (IGFBP-5) and chemokine receptor CXCR4 mRNAs were significantly upregulated in response to NANOG overexpression in androgen-deprived conditions. The relative CXCR4 mRNA levels were elevated B12 Â and B10 Â , and IGFBP5 was elevated B5 Â and B7 Â , respectively, in bicalutamide-treated pLVX-Nanog1 and pLVX-NanogP8 LNCaP cells relative to that in pLVX control cells (Figure 6e and Supplementary Table S3 ). Three CSC surface markers, CD133, ABCG2 and c-KIT, generally increased in response to NANOG overexpression, particularly, in spheres (Figure 6e ). Several other molecules examined also showed some alterations in androgen-deficient conditions (Figure 6e ), although these differences were generally less than two-fold.
Somewhat surprisingly, when we examined the same panel of genes in LNCaP cells cultured in regular serumcontaining media and treated with dox for 3-14 days, many of the same genes were also dynamically upregulated in response to NANOG1/NANOGP8 induction, which included both IGFBP5 and CXCR4, as well as CD133, ABCG2 and c-KIT (Figure 6f) . These results suggest that the alterations of these genes are also likely involved in mediating the general pro-tumorigenic effects in addition to the AI-specific effects of NANOG.
Further evidence that Nanog overexpression promotes CSC phenotypes and CSC properties
To further evaluate the cellular and molecular consequences of NANOG overexpression in other contexts, we continued the in vitro and in vivo studies using our inducible Du145 and MCF7 cells. NANOGP8 induction in Du145 cells, which are AI PCa cells and lack AR expression, promoted tumor regeneration in both ectopic (s.c.; Figure 7a ) and orthotopic (dorsal prostate or DP; Figure 7b ) sites. Curiously, pLVX-Nanog1 Du145 cells did not regenerate significantly larger tumors than pLVX control cells (Figures 7a and b ) despite overall similar expression levels of NANOG mRNA (Supplementary Figure S6a , right) and protein (not shown) in pLVX-Nanog1 and pLVX-NanogP8 Du145 tumors. pLVX-NanogP8 Du145 cell-derived orthotopic tumors had higher levels of c-Myc protein in comparison with either pLVX-Nanog1 or pLVX-control cells (Figure 7c ), perhaps partially accounting for the pro-tumorigenic activity of NANOGP8.
MCF-7 cells overexpressing NANOG, particularly NANOGP8, showed increased resistance to the chemotherapeutic drugs doxorubicine and paclitaxel, consistent with previous findings by others (Bourguignon et al., 2008) . To explore the potential mechanisms underlying the NANOG-conferred drug tolerance in MCF7 cells, we also used qRT-PCR quantification of more than a dozen genes (Figure 7e ). The results showed dynamic upregulation by NANOG1/ NANOGP8 of several pro-survival/detoxification genes, including Bcl-2, ABCG2, CD133 and ALDH1A1 (Figure 7e and Supplementary Table S3 ). IF staining confirmed increased CD133 protein in NANOGoverexpressing MCF7 cells (Figure 7f ). ALDH1A1 (ALDH1 isoform A1) is the primary ALDH isoform mediating the ALDEFLUOR phenotype (Ginestier et al., 2007) . Consistent with the upregulation of the ALDH1A1 mRNA, NANOG1/NANOGP8 overexpression greatly increased the percentage of ALDEFLUORpositive MCF7 cells (Figure 7g ). Significantly, both NANOG1 and NANOGP8 also increased the abundance of ALDEFLUOR þ Du145 cells (Supplementary Figure S6d) . In addition to the above four molecules, NANOG1/ NANOGP8 overexpression in MCF7 cells also upregulated, to lower levels, many of the other molecules examined, including c-Myc, OCT-4, SOX2, CD44, c-KIT, MMP9, TWIST and SNAIL (Figure 7e ).
Discussion

NANOGP8-expressing PCa cells possess CSC properties
In the present study, we first use differential qRT-PCR analysis to show that cultured PCa (and some other cancer) cells, and xenograft as well as patient tumors all predominantly express NANOGP8 mRNA, with NA-NOG1 mRNA generally below the detection threshold. These results corroborate our earlier preliminary report ) and are consistent with NANOG1 being restricted to pluripotent cells and downregulated during differentiation (Chambers et al., 2003; Chambers and Tomlinson, 2009 ). The NANOG1 gene in PCa cells such as PC3 seems to be epigenetically silenced as treatment with TSA, a histone deacetylase inhibitor, but not 5 0 -aza-deoxycytidine, a DNA methytransferase inhibitor, partially 'restores' NANOG1 expression . It is intriguing that somatic cancer cells, rather than reactivating the endogenous NANOG1 locus, express NANOG from the NANOGP8 locus. We are currently investigating how the NA-NOGP8 retrogene is transcriptionally activated in cancer cells.
Knocking down endogenous NANOG in cancer cells significantly diminishes their tumorigenic capacity . As tumor initiation is one of the defining characteristics of CSCs, our loss-of-function results suggest that NANOGP8-expressing cancer cells might possess CSC properties. This premise is born out in the present promoter-tracking studies: NANOGP8-expressing PCa cells are intrinsically unique in comparison with isogenic non-expressing cells, showing enhanced clonogenicity in vitro and tumorigenicity in vivo. Notably, NANOGP8-GFP PCa cells can regenerate tumors that contain GFP À cells as the majority, suggesting that NANOGP8 þ PCa cells can self-renew in vivo.
NANOG overexpression promotes CSC phenotypes and properties in vitro and in vivo
Our current NANOG gain-of-function studies further complement the earlier knockdown findings ) and indicate that NANOG overexpression is sufficient to confer upon cancer cells certain CSC properties and phenotypes. Thus, NANOG induction promotes clonogenic survival in LNCaP cells, drug resistance in MCF7 cells and, most importantly, tumor development in LNCaP and Du145 cells. Accompanying the manifestation of such biological properties of CSCs, NA-NOG overexpression enhances the expression of many CSC-associated molecules, including, among others, CD133, ABCG2, ALDH1A1 and CD44.
NANOG overexpression promotes AI phenotypes and castration-resistant PCa regeneration
One of the most significant findings from our study is that NANOG expression is associated with AI and castration resistance in PCa cells. The first hint for such an association comes from the promoter-tracking studies, in which we find that NANOGP8-expressing LNCaP cells possess extended and much enhanced survivability in androgen-deprived conditions. Subsequent gain-of-function studies provide convincing evidence that NANOG overexpression promotes clonogenicity and tumor regeneration of LNCaP cells in androgen-deprived conditions/hosts. These results suggest that NANOG might contribute to PCa progression to a hormone-refractory state. In support, wholegenome cDNA microarray analysis shows that NANOG is preferentially expressed in PCa cells that express low levels of PSA, the population naturally resistant to androgen blockade (Qin et al., unpublished observations) . In further support, NANOG overexpression also enhances tumor regeneration in AR À and AI Du145 cells.
What mechanisms might be responsible for NANOGconferred AI phenotypes and castration resistance? One mechanism is likely related to the NANOG-promoted CSC phenotypes and properties discussed above. Prostate CSCs seem to express low levels of AR and thus are intrinsically less dependent on AR signaling (Collins et al., 2005; Patrawala et al., 2006; Li et al., 2009) . In support of this connection, we have previously reported reciprocal nuclear expression between AR and NANOG , and we have shown here that NANOG-overexpressing LNCaP cells express lower levels of AR, especially in tumors developed in castrated hosts.
NANOG promotes the expression of other molecules such as Bcl-2, IGFBP-5 and CXCR4, which might also be involved in NANOG-mediated castration resistance in LNCaP cells. Bcl-2 is an antiapoptotic protein and its overexpression has been strongly implicated in the development of castration-resistant PCa (McDonnell et al., 1992) . IGFBP-5 mRNA and protein are upregulated in response to castration and exogenous IGFBP-5 stimulates the proliferation of immortalized prostate epithelial cells (Xu et al., 2007) . Also, overexpression of IGFBP-5 accelerates the proliferation of LNCaP cells in androgen-deprived conditions in a phosphatidylinositol-3-kinase-dependent manner (Miyake et al., 2000) . IGFBP-5 is known to regulate IGF-1 receptor signaling, which has been implicated in LNCaP (and LAPC-9) PCa progression to androgen independence (Nickerson et al., 2001) , and is required for the emergence of the CD133 þ drug-resistant PC9 cells (Sharma et al., 2010) . Finally, CXCR4 and its cognate chemokine CXCL12 have been implicated in PCa cell migration and invasion (Singh et al., 2004; Frigo et al., 2009) . A functional consequence of NANOG-promoted CXCR4 expression may be the enhanced migratory capacity of NANOGP8-expressing LNCaP AI tumor cells.
The mechanisms underlying the NANOG-mediated castration resistance are likely multi-faceted, and our ongoing research seeks to further address whether some of these CSC-and AI-associated molecules represent direct NANOG targets and exactly how NANOG promotes PCa AI progression.
NANOGP8 versus NANOG1: similarities and distinctions
Throughout the preceding discussions, we mostly used the term NANOG to 'generically' refer to the proteins encoded by both NANOG1 and NANOGP8, mainly because the predicted NANOG1 and NANOGP8 proteins are B99% identical . Multiple lines of evidence support the overt similarities between NANOG1 and NANOGP8 proteins. First, most currently used commercial anti-NANOG Abs are raised against NANOG1 but generally recognize the recombinant NANOGP8 proteins equally well . Second, both NANOG1 and NANOGP8 are induced, remarkably, to very similar levels in cancer cells (Figures 3b and c) . It is worth mentioning that the induced NANOG1 and NANOGP8 are both at much lower levels than endogenous NANOG1 levels in N-TERA cells (Figures 7b and c) , suggesting that somatic cancer cells might not be able to tolerate very high levels of NANOG as a result of unique biochemical mechanisms regulating NANOG turnover. Third, importantly, NANOG1 and NA-NOGP8 show similar biological effects in many experimental settings. For example, both NANOG1 and NANOGP8 promote castration-resistant LNCaP tumor development (Figures 5f and g) , increase c-Myc and decrease AR in AI tumors (Figures 6a and c) , and enhance the expression of many same genes such as CD133, IGFBP-5 and ABCG2 (Figures 6e and f,  and 7e ).
On the other hand, NANOGP8 is the predominant 'isoform' expressed in cancer cells and may, therefore, have evolved new functions distinct from those of NANOG1 in ESCs. In support, we have observed, in most assays, much more consistent biological effects with NANOGP8 overexpression compared with NANOG1 overexpression. For example, only NANOGP8 promotes, in LNCaP cells, AI sphere and AI foci formation, castration-resistant tumor development and cell migration ( Figure 5 ). Likewise, NANOGP8, but not NANOG1, promotes Du145 tumor development and c-Myc upregulation. At the molecular levels, NANOGP8 and NANOG1 seem to bind to chromatin-associated targets with different affinities (Figure 4) . Moreover, NANOGP8 and NANOG1 frequently induce different gene alterations even in the same cell types maintained under the identical conditions (Figures 6e and f, and 7e ). Finally, whole-genome ChIP-Seq analysis has shown that, although NANOG1 and NANOGP8 share B75% genomic binding sites, the two proteins show B25% distinct binding sites in the genome (Jeter et al., unpublished observations) . Further analysis of the ChIP-Seq data, together with our efforts to elucidate the unique biochemical properties and signaling partners of NANOG in cancer cells, and the interrelationship between AR/androgen signaling and NANOG, should greatly advance our understanding of the molecular mechanisms underlying the immortality of cancer cells and the development of castrationresistant PCa.
Materials and methods
Primary prostate tumor (HPCa) specimens and tumor processing HPCa samples were obtained at radical prostatectomy with patients' consent. Tumor pieces, designated as adenocarcinoma by pathological examination and classified as Gleason 6-9, were frozen in liquid nitrogen. For first-round xenotransplantation, small (B1-2 mm 2 ) tumor pieces were implanted subcutaneously into NOD/SCID-g mice. Early-passage HPCa tumor tissues were subject to enzymatic digestion (type-I collagenase, 50 U/ml DNase, 12 h), followed by trypsin digestion and discontinuous Percoll gradient purification. Lineage-positive cells including hematopoietic, endothelial and stromal cells were removed using an Ab cocktail and MACS (Miltenyi Biotec, Auburn, CA, USA) as previously described by Jeter et al. (2009) .
Quantitative RT-PCR Total RNA was extracted from cultured cancer cells or tumor pieces (frozen in liquid nitrogen) using an RNeasy RNA purification kit (Qiagen, Valencia, CA, USA). The ABI High-Capacity cDNA Archive kit (Applied Biosystems, Carlsbad, CA, USA) and random hexamers were used for cDNA synthesis. Quantitative PCR was performed by the MD Anderson Science-Park Molecular Biology Core Facility using an ABI Prism 7900HT (Applied Biosystems). The File Builder 3.1 software (Applied Biosystems) was used to design NANOG1-and NANOGP8-specific primers and probes ( Supplementary Table S1 ) required to discriminate between RNA species arising from either locus. A panel of gene-specific primer pairs was also used for further expression profiling by the SYBR Green method ( Supplementary Table S1 ). The experimental C t was calibrated against that of the GAPDH control product. All amplifications were performed in duplicate. The DDC t method was used to determine the amount of NANOG product relative to that expressed by the most benign PCa line, LNCaP (1-fold, 100%). For comparative gene expression profiling of pLVX cell lines, the RNA levels of a particular gene in the pLVX-NANOG1/P8 cells were presented relative to the pLVX control cells (1-fold, 100%).
Lentiviral constructs, packaging and transduction
The B3.8-kb human NANOGP8 promoter fragment was amplified from LNCaP cell genomic DNA using the 5 0 primer CTCGAGCATAGCTGCATTGGCAAAGA, incorporating an XhoI restriction site, and the 3 0 primer GGATCCATG AGGCAACCAGCTCAGTC, incorporating a BamHI restriction site, subcloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA) and inserted into RRL-PGK-GFP1 (Zufferey et al., 1998) as an XhoI-BamH1 fragment before the GFP transgene to generate RRL-NANOGP8-GFP. The RRL-based lentivirus was prepared as previously described by Jeter et al. (2009) . In brief, G418-selected 293FT cells (12 Â 10 6 per 15-cm dish) were transfected with the RRE (6 mg), REV (4 mg) and VSVg (4 mg) packaging plasmids, along with a lentiviral vector (6 mg), using Fugene-6 at a 1:2.7 ratio of DNA (mg) to transfection reagent (ml). Viral supernatants were ultracentrifuged to produce concentrated viral stocks. Cells were plated 24 h earlier and infected with the indicated volumes of virus, prepared in parallel, at approximately 50% cell density.
To create the pLVX-TetON-NANOG constructs, the NANOG1 cDNA from N-TERA cells or the NANOGP8 coding region derived from HPCa5 in pCR2.1 (Invitrogen) was sub-cloned into the pLVX-TetON expression vector (Clontech, Mountain View, CA, USA) by 5 0 NotI and 3 0 MluI restriction enzyme excision and ligation. All newly generated lentiviral vectors were characterized by restriction digestion and sequencing. The pLVX-based lentivirus was prepared according to the protocol of the Lenti-X Tet-ON Advanced Inducible Expression System (Clontech) and by using the Lenti-X packaging system.
Chromatin immunoprecipitation
ChIP assay was performed by following the manufacturer's instructions (Upstate, Charlottesville, VA, USA). Cultured pLVX LNCaP cells (that is, cells expressing pLVX, pLVX-Nanog1 or pLVX-NanogP8) were treated with dox (500 ng/ml) for 3-4 days prior to harvest. After cells were fixed, washed and collected, their DNA was sheared by sonication in 200 ml of lysis buffer. Then, 20 ml of sonicated DNA from each sample was purified and used as an input DNA control and the remainder of the DNA was pre-cleared. The chromatin-bound DNA was immunoprecipitated with an anti-NANOG Ab (H-155; Santa Cruz, Santa Cruz, CA, USA) and protein-A beads, and the DNA was eluted from the beads. The precipitated DNA was analyzed by PCR for 1 cycle at 95 1C for 2 min; 35 cycles at 95 1C for 20 s, 55 1C for 20 s and 72 1C for 30 s; and 1 cycle at 72 1C for 10 min. The PCR primers (see Supplementary Figure S4 ) included the distal E-cadherin promoter (À2273 to À1889 bp, 5 0 -ATCAGAGAGGTTGGTTCCA GTCC-3 0 and 5 0 -GCAATGGTGTGTTCTTGGCTCAC-3 0 ), the FGF4 promoter (À1567 to À1250 bp, 5 0 -CAACACAG CAAGTGAGGGATGG-3 0 and 5 0 -TTGAGGGCTCTTCTC TGAGGTG-3 0 ), the Gli1 promoter (À2991 to À2645 bp, 5 0 -CTTTCCATTCTGCCGTCTTCAG-3 0 and 5 0 -CGCTTTAC CCATCTCCCAACAC-3 0 ), the Hoxc13 promoter (À1116 to À781 bp, 5 0 -CTGAATCTCCCCCATTTTCCAC-3 0 and 5 0 -ACACTCTGCTTTACCTCGCTGG-3 0 ), the Oct4 promoter (À1928 to À1519 bp, 5 0 -CAGACAGACAAACATCAT CCCTCAC-3 0 and 5 0 -TCACACGAGATCCCCTTCAGAG AC-3 0 ), the c-Myc promoter (À1303 to À968 bp, 5 0 -GAA GCCTGAGCAGGCGGGGCAGG-3 0 and 5 0 -GCTTTGAT CAAGAGTCCCAG-3 0 ) and the GAPDH promoter (5 0 -ACTCTGCTCTGGGTGGTCATTG-3 0 and 5 0 -GGGTGCTG AACACTTGTAAGGAAG-3 0 ).
Abbreviations AD, androgen dependent; AI, androgen independent; CE, cloning efficiency; ChIP, chromatin immunoprecipitation; CSC, cancer stem cells; dox, doxycycline; DP, dorsal prostate; EMT, epithelial mesenchymal transition; ESCs, embryonic stem cells; HPCa, human prostate cancer patient samples; NOD/SCID, non-obese severe combined immunodeficient mice; PCa, prostate cancer; qRT-PCR, quantitative reversetranscription polymerase chain reaction; s.c, subcutaneous; SP, side population; TSS, transcription start site; UTR, untranslated region.
